Skip to main content

Table 5 Treatment outcome by FCGR3A genotype, KRAS or BRAF mutational status, and therapy received

From: FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab

 

FLOX

FLOX + cetuximab

 
 

F/F

F/V

V/V

F/F

F/V

V/V

Interaction P-value

KRAS wild-type (N =268)

Number of patients

N = 39

N = 38

N = 9

N = 87

N = 73

N = 22

 

Response

44% (17/39)

45% (17/38)

56% (5/9)

48% (42/87)

51% (37/73)

55% (12/22)

0.95*

PFS

7.8

9.0

8.4

8.0

7.3

11.8

0.72†

OS

23.1

20.5

25.2

17.6

25.9

20.5

0.97†

KRAS mutated (N =169)

Number of patients

N = 28

N = 21

N = 6

N = 59

N = 46

N = 9

 

Response

36% (10/28)

48% (10/21)

50% (3/6)

51% (30/59)

39% (18/46)

33% (3/9)

0.28*

PFS

7.8

8.1

4.0

8.3

7.0

6.9

0.19†

OS

18.5

24.3

17.1

21.3

17.7

16.4

0.63†

BRAF wild-type (N = 359)

Number of patients

N = 56

N = 47

N = 12

N = 126

N = 94

N = 24

 

Response

45% (25/56)

49% (23/47)

50% (6/12)

52% (65/126)

48% (45/94)

63% (15/24)

0.71*

PFS

7.9

9.1

7.8

8.3

7.6

11.5

0.58†

OS

23.8

23.6

19.7

20.6

22.9

20.5

0.93†

BRAF mutated (N = 46)

Number of patients

N = 8

N = 7

N = 2

N = 10

N = 14

N = 5

 

Response

13% (1/8)

14% (1/7)

50% (1/2)

20% (2/10)

29% (4/14)

0% (0/5)

0.99*

PFS

5.9

4.3

4.4

4.2

5.4

4.6

0.87†

OS

9.5

9.4

5.2

10.8

8.9

10.3

0.66†

  1. *Logistic regression, †Cox proportional hazard model.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us